Long-acting Somatostatin Analogues in the Treatment of Unresectable/Metastatic Neuroendocrine Tumors

Publication date: Available online 25 July 2017
Source:Seminars in Oncology
Author(s): Thomas Enzler, Tito Fojo
Neuroendocrine tumors (NETs) are a relatively rare and heterogeneous group of neoplasms with an annual incidence of ~35 cases per 100,000 people in the U.S. The updated World Health Organization (WHO) classification system of gastroenteropancreatic (GEP-) NETs categorizes these tumors according to site of origin, clinical syndrome, and degree of differentiation. Well-differentiated NETs arising from the gastrointestinal tract or lungs (formerly known as carcinoid tumors) are often indolent and slowly growing. In contrast, poorly differentiated neuroendocrine carcinomas (NECs) are aggressive and have a poor prognosis. Due to their insidious onset, most NETs are diagnosed at an advanced stage and a curative approach is not possible. In these patients, medical therapy is limited to disease control including relief of symptoms that arise from overproduction of peptide hormones by the tumors. Somatostatin analogues (SSAs) have remained the mainstay of symptoms control. In addition to symptoms control, clinical data also support an anti-proliferative effect of SSAs in patients with well to moderately differentiated NETs. Long-acting SSAs have greatly facilitated their use. This review will focus on two long acting SSAs, octreotide LAR and lanreotide and their use in the clinical setting. Information necessary to assess their relative merits is summarized. We conclude these two therapies are interchangeable making value a very important consideration in their use.



http://ift.tt/2tAkWRT